The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

Merck & Co Inc. has become a top contender for the most profitable value stock, but it faces some challenges. Merck boasts a forward P/E ratio of 10.36 and TTM net income of $17.117 billion. Despite ...

We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at ...

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in ...

I disagree with the editorial board’s characterization of Mahmoud Khalil as “a supporter of Hamas” rather than as a supporter ...

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.

Feb. 19, 2025 – A vaccine for pregnant women that protects babies from respiratory syncytial virus (RSV) appears safe, according to two new studies that give researchers hope for widespread ...

In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.

The White House pulled the nomination of former Rep. Dave Weldon, (R-FL), to head the Centers of Disease Control and Prevention on Thursday morning, just hours before he was set to appear before the ...

A federal judge granted summary judgment in favor of Merck for part of the litigation involving the HPV vaccine, Gardasil.